Nluc Reporter Cell Line - HPAC

The HPAC cell line, short for Human Pancreatic Adenocarcinoma cell line, is a well-established in vitro model system derived from a primary pancreatic tumor. These cells originate from epithelial cells and exhibit characteristics of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. HPAC cells are known to express epithelial cell-specific markers such as cytokeratins, and also express several oncogenes and tumor suppressor genes specific to pancreatic cancer. This cell line has played a crucial role in advancing our understanding of pancreatic cancer biology, including studies on tumor growth, invasion, metastasis, and chemoresistance. Researchers utilize HPAC cells to investigate the molecular pathways involved in pancreatic cancer development and progression, and to evaluate potential therapeutic agents. Furthermore, HPAC cells have been used in xenograft models, implanted into immunodeficient mice, to study tumor growth and response to treatment in a more physiologically relevant environment.

The Nluc reporter cell line - HPAC is a genetically engineered variant of the HPAC cell line in which the NanoLuc luciferase (Nluc) reporter gene has been introduced. Nluc, derived from the deep-sea shrimp Oplophorus gracilirostris, is a novel luciferase with significant advantages over traditional luciferases (e.g., firefly luciferase or Renilla luciferase). It is smaller (approximately 19 kDa), brighter, and more stable, allowing for high-sensitivity detection with low background signal. In the Nluc reporter cell line - HPAC, the Nluc gene is typically placed under the control of specific regulatory elements (e.g., promoters or response elements), thus linking Nluc expression to the activity of a particular pathway or target gene. This enables real-time monitoring of cellular events, including gene expression, protein-protein interactions, and signal transduction. The applications of this reporter gene cell line are wide-ranging, from high-throughput drug screening (testing the ability of compounds to modulate specific targets) to mechanistic studies (exploring the regulatory mechanisms of gene expression in pancreatic cancer).